

In FY21, we initiated our 'Buy' call on the Pharma sector after being Negative/Neutral since FY16. Since then **our Pharma basket has given returns of 101% v/s the Nifty's return of 70% (an outperformance of 31%)**. While we replaced Biocon (BIOS) with Lupin (LPC) in May'20, **we have now replaced Abbott India (ABT) with Sun Pharma (SUNP)**. Through this report, we are reiterating our positive view on the Pharma sector.

#### **LAURUS a winner; Expect SUNP to shine**

Within our recommended stocks, Laurus Labs (LAURUS) with 4x returns transformed into a massive wealth creator in FY21, followed by Dr Reddy's (DRL), Ajanta Pharma (AJP), and LPC with +25% returns each. ABT with negative returns was a laggard. LAURUS has seen EPS upgrades of ~250% for FY22E (from EPS of INR7.4/share in Apr'20 to INR19.5/share currently), driven by significant ramp-up in antiretroviral (ARV) portfolio and incremental order inflows. On the other hand, ABT has seen earnings downgrade and multiple de-ratings due to the Covid-19 induced weak Domestic Formulation (DF) business and competition in key drugs (such as Duphaston/Duphalac). While ABT's DF business is expected to grow FY22E onwards, we expect product-specific competition to remain elevated; and hence, we have removed it from our Focus-5 list.

#### **Multiple headwinds earlier dented SUNP's performance**

Over the last 4-5 years, SUNP has massively underperformed, driven by multiple structural issues such as (a) pricing pressure in the US generics market, which impacted both Taro and SUNP's core US business, (b) heavy investments in the Speciality portfolio, and (c) lower growth in DF due to SUNP's acquisition of Ranbaxy (RBX) whose portfolio is Acute heavy, which led to margin contraction and significant earnings downgrades. Further, the company faced an adverse US Court ruling on price fixing during FY13-15 for certain drugs. Apart from these, few corporate governance issues like the holding structure of its DF business led to multiple de-ratings.

#### **SUN PHARMA entering into an earnings upgrade cycle**

Most of the headwinds are now behind for SUN PHARMA and we believe the company is entering into an earnings upgrade cycle driven by:

- (a) change in the business mix – from being a heavily US-focused company five years ago to having a well-diversified geographical presence currently,
- (b) improvement in Speciality business – it has seen significant traction over the last six months in key products (Illiumiya market share gain, ramp-up in Odomozo/Cequa and shifting market in Absorica), and
- (c) stabilisation in Indian formulation business post restructuring (Aditya Medi sales) and base effect of FY21 (Covid-19 induced).

#### **Outlook and view**

With tailwinds in place for SUN PHARMA, we expect the company to see margin improvement by 100-200bps and to deliver 20% EPS CAGR over FY21-FY23E. An upside in earnings upgrade could emerge from early resolution of its Halol facility.

#### **Key risks:**


- (a) Higher market share loss in Absorica, and
- (b) Over 5% decline in Taro portfolio.

#### **Tactical BUY**


**SUN PHARMA TP INR 757**  
**AJANTA PHARMA TP INR 2258**  
**LUPIN TP INR 1213**  
**DR REDDY TP INR 5416**  
**LAURUS LAB TP INR 520**

Date: April 11, 2021


**Exhibit 1: Business mix has changed and is more broad based, which will reduce geographical-specific risks**




**Exhibit 2: US Speciality business is now stabilizing; market share ramp-up over last six months a surprise**




**Exhibit 3: Expect RBX's Acute portfolio's growth to normalize; in turn, SUNP should outperform IPM again**



**Exhibit 4: EM business delivered 11% CAGR post RBX consolidation; we expect the trend to continue**



**Exhibit 5: Margins have bottomed out due to FDA related compliance costs and lower investments in Speciality; R&D is more or less stable**



Source: Edelweiss Wealth Research

SUN PHARMA			SOTP	PAT/NW	Multiple	Equity	Per Share
CMP	635 P/BV	3.18	Core	7266	25.0	181653	757
Book value	189 P/E	30	One Time	DCF			0
Face value	1 RONW	11%					
Mcap Rscr.	152356 ROCE	11%	O/S			240	757
Potential Upside	19% EPS CAGR	19%	Upside				19%

ShareHolding	1QFY21	2QFY21	3QFY21	Peer Set	CMP	FY22E	FY23E	P/E FY22E	P/E FY23E
Promoter	55%	55%	54%	SUN	637	25	29	25	22
FII	13%	12%	12%	LUPIN	1079	38	47	28	23
MF/FI/Ins	20%	20%	21%	CADILA	514	21	23	24	22
Public	13%	12%	12%	CIPLA	883	34	42	26	21
Pledge	10%	9%	9%	Glenmark	530	36	41	15	13
				DrReddy	4760	190	232	25	21
				Avg				24	20

**Income Statement (Cost)**

Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E
Sales	29066	32838	33792	37132	40578
COGS	22758	25848	24989	27392	29635
EBITDA	6308	6990	8803	9740	10943
margin%	22%	21%	26%	26%	27%
Other Income	1025	636	998	1012	1247
Interest	555	303	748	450	450
Depreciation	1762	2053	2283	2348	2413
PBT	5016	5270	6770	7954	9327
Tax	625	823	1219	1432	1679
Tax Rate	12%	16%	18%	18%	18%
PAT	4391	4447	5551	6523	7649
Ext Item	0	0	0	0	0
Minority Interest	420	418	444	326	382
Profit from Asso/Sub	0	0	0	0	0
APAT	3971	4030	5107	6196	7266
EPS (Core)	16.6	16.8	21.3	25.8	30.3
BV	173	189	199	215	234

**Cash Flow Statement**

Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E
APAT	3971	4030	5107	6196	7266
Depreciation	1762	2053	2283	2348	2413
Non Cash Adj	0	0	0	0	0
Change In WC	(5130)	646	(315)	(1103)	(1139)
Operating CF	603	6729	7074	7441	8540
Investing CF	(5498)	(5670)	(1000)	(1000)	(1000)
Fixed Asset	(4738)	(3429)	(1000)	(1000)	(1000)
Investment	(760)	(2241)	0	0	0
Financing CF	(747)	(2374)	(5841)	(2526)	(2526)
Debt	129	(2199)	(3315)	0	0
Equity	1370	2352	0	0	0
Dividend	(2246)	(2526)	(2526)	(2526)	(2526)
Change in Cash	(5642)	(1315)	233	3914	5014
Cash at Beg	9929	7276	6488	6721	10635
Cash at End	4288	5961	6721	10635	15648

**Balance Sheet**

Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E
<b>Source of Fund</b>	<b>56242</b>	<b>58774</b>	<b>58484</b>	<b>62480</b>	<b>67602</b>
Equity	240	240	240	240	240
Researve	41169	45025	47605	51275	56015
Share Warrant	0	0	0	0	0
Networth	41409	45264	47845	51515	56255
Minority	3314	3860	4304	4630	5013
Debt	11519	9649	6334	6334	6334
Secured	10505	8057	5000	5000	5000
UnSecured	1014	1592	1334	1334	1334
<b>Application of Fund</b>	<b>56242</b>	<b>58774</b>	<b>58457</b>	<b>62544</b>	<b>67702</b>
GrossBlock	31687	35116	36116	37116	38116
Depreciation	9851	12269	14552	16899	19312
Net Block	21837	22847	21564	20217	18804
CWIP	1411	1220	1638	2055	2473
Good Will	0	0	0	0	0
Investment	7903	10143	10143	10143	10143
Cash	7276	6488	6721	10635	15648
Net CA ex Cash	11495	10849	11164	12268	13406
Net Deff Ass	6321	7227	7227	7227	7227

**Margin, Ratios and Growth Matrix**

	FY19	FY20	FY21	FY22E	FY23E
EBITDA %	22%	21%	26%	26%	27%
PAT%	14%	12%	15%	17%	18%
RONW		9%	11%	12%	13%
ROCE		8%	11%	12%	12%
P/E	38	38	30	25	21
P/BV	4	3	3	3	3
EV/EBITDA	24.8	22.2	17.3	15.2	13.1
D/E	0.3	0.2	0.1	0.1	0.1
Sales Growth		13.0%	2.9%	9.9%	9.3%
EPS Growth		1%	27%	21%	17%

**Sales Mix**

Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E
US	5999	6466	7040	8483	9971
INDIA	2622	2895	3455	4045	4530
ROW	2890	3284	3560	4082	4694
API	2494	2693	3245	3365	3701
Proprietary	617	1073	357	429	515

\*Bull case EPS

## Pharmaceutical

## Financials – Lupin

Lupin				SOTP	PAT/NW	Multiple	Equity	Per Share	
CMP	1070	P/BV	3.28	Core	2496	22.0	54903	1213	
Book value	310	P/E	47	One Time	DCF			0	
Face value	2	RONW	7%						
Mcap Rscr.	48418	ROCE	6%	O/S			45	1213	
Potential Upside	13%	EPS CAGR	56%	Upside				13%	

ShareHolding	1QFY21	2QFY21	3QFY21	Peer Set	CMP	FY22E	FY23E	P/E FY22E	P/E FY23E
Promoter	47%	47%	47%	SUN	637	25	29	25	22
FII	21%	20%	19%	LUPIN	1079	38	47	28	23
MF/FI/Ins	19%	20%	21%	CADILA	514	21	23	24	22
Public	13%	13%	13%	CIPLA	883	34	42	26	21
Pledge	0%	0%	0%	Glenmark	530	36	41	15	13
				DrReddy	4760	190	232	25	21
				Avg				24	20

Income Statement (Cost)						Cash Flow Statement					
Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E	Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E
Sales	16718	16393	15346	17286	19345	APAT	940	445	1027	1900	2496
COGS	14017	13847	12819	13971	15422	Depreciation	1085	1106	1123	1185	1234
EBITDA	2701	2546	2528	3315	3923	Non Cash Adj	0	0	0	0	0
margin%	16%	16%	16%	19%	20%	Change In WC	(292)	126	406	(752)	(798)
Other Income	545	508	558	876	1150	Operating CF	1733	1677	2556	2333	2931
Interest	308	368	350	350	350	Investing CF	(3906)	(500)	(700)	(700)	(700)
Depreciation	1085	1106	1123	1185	1234	Fixed Asset	(1872)	(500)	(700)	(700)	(700)
PBT	1853	1579	1612	2656	3488	Investment	(2034)	0	0	0	0
Tax	902	1134	564	717	942	Financing CF	579	(1671)	(265)	(265)	(265)
Tax Rate	49%	72%	35%	27%	27%	Debt	1353	(1497)	0	0	0
PAT	951	445	1048	1939	2547	Equity	(510)	90	0	(0)	0
Ext Item	0	0	0	0	0	Dividend	(265)	(265)	(265)	(265)	(265)
Minority Interest	12	0	21	39	51	Change in Cash	(1594)	(495)	1591	1369	1967
Profit from Asso/Sub	0	0	0	0	0	Cash at Beg	(842)	987	493	2084	3452
APAT	940	445	1027	1900	2496	Cash at End	987	493	2084	3452	5419
EPS (Core)	20.8	9.8	22.7	42.0	55.2						
BV	304	310	327	363	412						

Balance Sheet						Margin, Ratios and Growth Matrix					
Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E		FY19	FY20	FY21	FY22E	FY23E
Source of Fund	23386	22159	22942	24616	26898	EBITDA %	16%	16%	16%	19%	20%
Equity	91	91	91	91	91	PAT%	6%	3%	7%	11%	13%
Researve	13652	13922	14684	16319	18550	RONW		3%	7%	12%	14%
Share Warrant	0	0	0	0	0	ROCE		4%	6%	10%	11%
Networth	13742	14013	14775	16410	18641	P/E	52	109	47	25	19
Minority	47	47	68	107	158	P/BV	4	3	3	3	3
Debt	9597	8100	8100	8100	8100	EV/EBITDA	21.1	22.0	21.5	16.0	13.0
Secured	1497	0	0	0	0	D/E	0.7	0.6	0.5	0.5	0.4
UnSecured	8100	8100	8100	8100	8100	Sales Growth		-1.9%	-6.4%	12.6%	11.9%
Application of Fund	23386	22159	22948	24627	26858	EPS Growth		-53%	131%	85%	31%
GrossBlock	15732	16232	16932	17632	18332						
Depreciation	4645	5751	6875	8060	9294	Sales Mix					
Net Block	11087	10481	10057	9572	9038	Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E
CWIP	1640	1640	1667	1711	1711	US	5593	5821	5499	6163	6763
Good Will	0	0	0	0	0	INDIA	4638	5139	5320	6035	6850
Investment	2295	2295	2295	2295	2295	ROW	780	1213	1506	1936	2461
						EU	1191	1236	1288	1369	1437
Cash	987	493	2084	3452	5419	API	1346	1300	1465	1509	1554
Net CA ex Cash	6481	6355	5949	6701	7500						
Net Deff Ass	895	895	895	895	895						

\*Bull case EPS

Ajanta Pharma					SOTP	PAT/NW	Multiple	Equity	Per Share										
CMP			1725	P/BV	4.36	Core	999	20.0	19971	2258									
Book value			319	P/E	21	One Time	DCF			0									
Face value			2	RONW	23%														
Mcap Rscr.			15258	ROCE	23%	O/S			9	2258									
Potential Upside			31%	EPS CAGR	18%	Upside				31%									
ShareHolding		2QFY21		3QFY21		4QFY21		Peer Set		CMP		FY22E		FY23E		P/E FY22E		P/E FY23E	
Promoter		71%		70%		70%		SUN		637		25		29		25		22	
FII		8%		8%		8%		LUPIN		1079		38		47		28		23	
MF/FI/Ins		12%		12%		13%		CADILA		514		21		23		24		22	
Public		10%		9%		9%		CIPLA		883		34		42		26		21	
Pledge		16%		15%		15%		Glenmark		530		36		41		15		13	
								DrReddy		4760		190		232		25		21	
								Avg								24		20	
Income Statement (Cost)						Cash Flow Statement													
Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E	Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E								
Sales	2055	2588	2889	3228	3625	APAT	388	474	718	853	999								
COGS	1497	1905	1871	2066	2318	Depreciation	14	1	1	2	1								
EBITDA	558	683	1017	1162	1307	Non Cash Adj	0	0	0	0	0								
margin%	27%	26%	35%	36%	36%	Change In WC	(55)	106	(64)	(72)	(85)								
Other Income	29	92	66	115	177	Operating CF	347	581	655	782	915								
Interest	0	12	0	0	0	Investing CF	(200)	(300)	(150)	(150)	(150)								
Depreciation	72	93	100	108	116	Fixed Asset	(200)	(300)	(150)	(150)	(150)								
PBT	515	670	983	1169	1368	Investment	0	0	0	0	0								
Tax	127	196	265	316	369	Financing CF	(41)	(41)	(41)	(41)	(41)								
Tax Rate	25%	29%	27%	27%	27%	Debt	0	0	0	0	0								
PAT	388	474	718	853	999	Equity	0	0	0	0	0								
Ext Item	0	0	0	0	0	Dividend	(41)	(41)	(41)	(41)	(41)								
Minority Interest	0	0	0	0	0	Change in Cash	106	240	463	591	723								
Profit from Asso/Sub	0	0	0	0	0	Cash at Beg	93	199	438	902	1493								
APAT	388	474	718	853	999	Cash at End	199	438	902	1493	2216								
EPS (Core)	43.9	53.6	81.2	96.5	112.9														
BV	270	319	395	487	595														
Balance Sheet						Margin, Ratios and Growth Matrix													
Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E		FY19	FY20	FY21	FY22E	FY23E								
Source of Fund	2403	2836	3512	4324	5281	EBITDA %	27%	26%	35%	36%	36%								
Equity	18	18	18	18	18	PAT%	19%	18%	25%	26%	28%								
Researve	2370	2803	3479	4291	5248	RONW		18%	23%	22%	21%								
Share Warrant	0	0	0	0	0	ROCE		19%	23%	22%	21%								
Networth	2388	2821	3497	4309	5266	P/E	39	32	21	18	15								
Minority	0	0	0	0	0	P/BV	6	5	4	4	3								
Debt	15	15	15	15	15	EV/EBITDA	27.2	21.7	14.1	11.9	10.0								
Secured	2	2	2	2	2	D/E	0.0	0.0	0.0	0.0	0.0								
UnSecured	13	13	13	13	13	Sales Growth		25.9%	11.6%	11.7%	12.3%								
						EPS Growth		22%	51%	19%	17%								
Application of Fund	2403	2835	3512	4324	5281														
GrossBlock	1601	1901	2051	2201	2351	Sales Mix													
Depreciation	421	514	614	722	838	Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E								
Net Block	1181	1387	1437	1479	1514	India	690	769	799	915	1049								
CWIP	217	211	310	416	531	AFRICA	503	594	615	680	756								
						ASIA	528	674	828	911	1002								
Good Will						USA	283	514	616	705	794								
Investment	190	190	190	190	190	LATAM	10	9	11	17	25								
Cash	101	438	902	1493	2216														
Net CA ex Cash	658	552	617	689	774														
Net Deff Ass	56	56	56	56	56														

\*Bull case EPS

DRREDDY					SOTP	PAT/NW	Multiple	Equity	Per Share		
CMP			4760	P/BV	4.48	Core	4092	22.0	90017	5416	
Book value			939	P/E	36	One Time	DCF			0	
Face value			5	RONW	13%						
Mcap Rscr.			79111	ROCE	12%	O/S			17	5416	
Potential Upside			14%	EPS CAGR	36%	Upside				14%	
ShareHolding		1QFY21	2QFY21	3QFY21	Peer Set	CMP	FY22E	FY23E	P/E FY22E	P/E FY23E	
Promoter		27%	27%	27%	SUN	637	25	29	25	22	
FII		29%	30%	29%	LUPIN	1079	38	47	28	23	
MF/FI/Ins		15%	14%	15%	CADILA	514	21	23	24	22	
Public		29%	30%	29%	CIPLA	883	34	42	26	21	
Pledge		0%	0%	0%	Glenmark	530	36	41	15	13	
					DrReddy	4760	190	232	25	21	
					Avg				24	20	
Income Statement (Cost)					Cash Flow Statement						
Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E	Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E
Sales	14941	16439	18649	21539	24320	APAT	1868	187	2218	2965	4092
COGS	12380	13374	14464	16154	17510	Depreciation	578	1163	1249	1482	1559
EBITDA	2561	3064	4186	5385	6810	Non Cash Adj	0	(1676)	4	4	4
margin%	17%	19%	22%	25%	28%	Change In WC	305	516	(646)	(858)	(826)
Other Income	352	625	90	88	235	Operating CF	2751	190	2825	3593	4829
Interest	69	98	57	65	57	Investing CF	2149	(1200)	(3000)	(1000)	(1000)
Depreciation	578	1163	1249	1482	1559	Fixed Asset	2438	(1110)	(3000)	(1000)	(1000)
PBT	2298	2484	2992	3948	5450	Investment	(289)	(91)	0	0	0
Tax	430	621	778	987	1363	Financing CF	(1650)	(240)	155	(567)	(267)
Tax Rate	19%	25%	26%	25%	25%	Debt	(1233)	(1628)	321	(300)	0
PAT	1868	1863	2214	2961	4088	Equity	(149)	1656	101	0	0
Ext Item	0	(1676)	4	4	4	Dividend	(267)	(267)	(267)	(267)	(267)
Minority Interest	0	0	0	0	0	Change in Cash	3250	(1250)	(21)	2026	3562
Profit from Asso/Sub	1868	1863	2214	2961	4088	Cash at Beg	563	3813	205	184	2210
APAT	1868	187	2218	2965	4092	Cash at End	3813	2563	184	2210	5772
EPS (Core)	112.6	11.2	133.4	178.4	246.2						
BV	845	939	1062	1224	1454						
Balance Sheet					Margin, Ratios and Growth Matrix						
Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E		FY19	FY20	FY21	FY22E	FY23E
Source of Fund	18159	18089	20461	22859	26684	EBITDA %	17%	19%	22%	25%	28%
Equity	83	83	83	83	83	PAT%	13%	1%	12%	14%	17%
Researve	13994	15616	17567	20265	24089	RONW		1%	13%	16%	18%
Share Warrant	-54	-101	0	0	0	ROCE		11%	12%	14%	17%
Networth	14024	15599	17650	20348	24172	P/E	42	423	36	27	19
Minority	0	0	0	0	0	P/BV	6	5	4	4	3
Debt	4136	2490	2812	2512	2512	EV/EBITDA	32.4	26.6	19.5	14.7	11.1
Secured	3838	2210	2532	2232	2232	D/E	0.3	0.2	0.2	0.1	0.1
UnSecured	297	280	280	280	280	Sales Growth		10.0%	13.4%	15.5%	12.9%
						EPS Growth		-90%	1086%	34%	38%
Application of Fund	18159	18090	20459	22858	26684	Sales Mix					
GrossBlock	14999	16108	19108	20108	21108	Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E
Depreciation	7808	9258	10507	11989	13548	US	5999	6466	7040	8483	9971
Net Block	7191	6850	8601	8119	7560	INDIA	2622	2895	3455	4045	4530
CWIP	2934	1535	1527	1523	1519	ROW	2890	3284	3560	4082	4694
						API	2494	2693	3245	3365	3701
Good Will	0	1	2	3	4	Proprietary	617	1073	357	429	515
Investment	2587	2678	2678	2678	2678						
Cash	223	205	184	2210	5772						
Net CA ex Cash	4375	4891	5537	6395	7221						
Net Deff Ass	850	1930	1930	1930	1930						

\*Bull case EPS

## Pharmaceutical

## Financials – Laurus Lab

Laurus Lab					SOTP	PAT/NW	Multiple	Equity	Per Share	
CMP		420	P/BV	8.58	Core	1264	22.0	27813		520
Book value		33	P/E	25	One Time	DCF				0
Face value		2	RONW	40%						
Mcap Rscr.		22451	ROCE	29%	O/S			53		520
Potential Upside		24%	EPS CAGR	20%	Upside					24%

ShareHolding	2QFY21	3QFY21	4QFY21	Peer Set	CMP	FY22E	FY23E	P/E FY22E	P/E FY23E
Promoter	32%	29%	27%	Granules	341	24	31	14	11
FII	21%	20%	21%	Neuland Lab	2388	76	97	32	25
MF/FI/Ins	6%	4%	4%	Aarti Drug	734	40	52	18	14
Public	41%	47%	48%	Laurus Lab	421	20	24	21	18
Pledge	16%	16%	1%	Avg				21	17

Income Statement (Cost)						Cash Flow Statement					
Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E	Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E
Sales	2292	2832	4516	5329	6330	APAT	0	0	881	1029	1264
COGS	1936	2267	3080	3659	4306	Depreciation	0	0	203	254	305
EBITDA	356	565	1436	1670	2024	Non Cash Adj	0	0	(1)	(1)	(1)
margin%	16%	20%	32%	31%	32%	Change In WC	0	0	(369)	(248)	(306)
Other Income	16	6	6	10	69	Operating CF	298	347	714	1035	1263
Interest	88	90	95	90	81	Investing CF	(253)	(221)	(600)	(600)	(600)
Depreciation	164	187	203	254	305	Fixed Asset	0	0	(600)	(600)	(600)
PBT	120	294	1144	1336	1708	Investment	0	0	0	0	0
Tax	26	38	263	307	444	Financing CF	(45)	(128)	(92)	(142)	(50)
Tax Rate	22%	13%	23%	23%	26%	Debt	0	0	(57)	(100)	0
PAT	94	255	881	1029	1264	Equity	0	0	0	0	0
Ext Item	(1)	(1)	(1)	(1)	(1)	Dividend	0	0	(35)	(42)	(50)
Minority Interest	0	0	0	0	0	Change in Cash	(0)	(1)	23	293	613
Profit from Asso/Sub	0	0	0	0	0	Cash at Beg	3	3	2	25	318
APAT	94	256	881	1029	1264	Cash at End	3	2	25	318	930
EPS (Core)	1.8	4.8	16.5	19.3	23.7						
BV	29	33	49	67	90						

Balance Sheet						Margin, Ratios and Growth Matrix					
Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E		FY19	FY20	FY21	FY22E	FY23E
Source of Fund	2685	2950	3740	4627	5842	EBITDA %	16%	20%	32%	31%	32%
Equity	106	107	107	107	107	PAT%	4%	9%	20%	19%	20%
Researve	1447	1658	2505	3493	4707	RONW		15%	40%	33%	30%
Share Warrant	5	5	5	5	5	ROCE		12%	29%	27%	26%
Networth	1558	1770	2616	3604	4819	P/E	237	88	25	22	18
Minority	0	0	0	0	0	P/BV	14	13	9	6	5
Debt	1126	1180	1123	1023	1023	EV/EBITDA	66.2	41.9	16.4	13.9	11.1
Secured	1016	875	1000	900	900	D/E	0.7	0.7	0.4	0.3	0.2
UnSecured	110	305	123	123	123	Sales Growth		23.6%	59.5%	18.0%	18.8%
						EPS Growth		170%	244%	17%	23%
Application of Fund	2685	2950	3739	4628	5841						
GrossBlock	2105	2388	2988	3588	4188						
Depreciation	476	661	864	1118	1423						
Net Block	1629	1726	2123	2469	2764						
CWIP	110	67	71	72	72						
Good Will											
Investment	3	3	0	0	0						
Cash	3	2	25	318	930						
Net CA ex Cash	813	1010	1379	1627	1933						
Net Deff Ass	126	141	141	141	141						

Sales Mix					
Rs.Cr.	FY19	FY20	FY21	FY22E	FY23E
ARV	1395	1086	1624	1705	1705
ONCO	218	211	290	319	350
API	369	324	394	433	541
Synthesis	255	385	573	745	969
FDF	55	825	1636	2127	2765

\*Bull case EPS

**Edelweiss Broking Limited**, 1st Floor, Tower 3, Wing B, Kohinoor City Mall, Kohinoor City, Kiroi Road, Kurla(W)  
Board: (91-22) 4272 2200

---

**Vinay Khattar**  
Head Research  
[vinay.khattar@edelweissfin.com](mailto:vinay.khattar@edelweissfin.com)

---



## Disclaimer

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its Associates (list available on [www.edelweissfin.com](http://www.edelweissfin.com)) are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231; Name of the Compliance Officer: Mr. Brijmohan Bohra, Email ID: [complianceofficer.ebl@edelweissfin.com](mailto:complianceofficer.ebl@edelweissfin.com) Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098; Tel. 18001023335/022-4272200/022-40094279

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No. INH000000172 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject EBL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. EBL reserves the right to make modifications and alterations to this statement as may be required from time to time. EBL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. EBL is committed to providing independent and transparent recommendation to its clients. Neither EBL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of EBL. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of EBL and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the EBL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. EBL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or EBL's associates may have financial interest in the subject company. EBL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

EBL has financial interest in the subject companies: No

EBL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years.

A graph of daily closing prices of the securities is also available at [www.nseindia.com](http://www.nseindia.com)

### Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimer for U.S. Persons

## Disclaimer

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the “1934 act”) and under applicable state laws in the United States. In addition Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the “Advisers Act” and together with the 1934 Act, the “Acts”), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. “U.S. Persons” are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed “US Persons” under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

### Additional Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”).

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the “Order”); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”).

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

### Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian persons.

This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.

### Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)

Edelweiss Broking Limited (“EBL” or “Research Entity”) is regulated by the Securities and Exchange Board of India (“SEBI”) and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited (“Edelweiss”) in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH000000172.